A Study for Patients With Schizophrenia

• Status: Completed
• Trial end date: 2008-10-01

Summary

The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.

• Phase: Phase 2

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Olanzapine